NEWARK, Del. — According to Future Market Insights, the global ESR1 mutated metastatic breast cancer diagnostics market is projected to grow from USD 64.61 million in 2025 to USD 92.92 million by 2035, registering a 3.7% CAGR during the forecast period. Demand is being supported by the increasing diagnosis of metastatic breast cancer, wider adoption of precision medicine, and the need for earlier identification of treatment-resistance mutations.
The market is moving toward molecular diagnostics that can support treatment selection and ongoing monitoring of ESR1 mutations. NGS-based tests are expected to remain the leading test type, while plasma-based testing is gaining momentum because liquid biopsy can provide a less invasive method for monitoring circulating tumor DNA.
👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16943
Key Market Highlights
- Market valuation: USD 64.61 million in 2025, projected to reach USD 92.92 million by 2035.
- Growth rate:7% CAGR from 2025 to 2035.
- Leading test type: NGS-based tests, accounting for 3% of market share in 2025.
- Fastest-growing sample type: Plasma, projected to expand at a 3% CAGR from 2025 to 2035.
- Leading end user: Hospital-associated laboratories, with 65% market share in 2025.
- Fastest-growing country: China, with a 2% CAGR.
- Trailing country: United States, with a 7% CAGR.
Global Segment Leaders
NGS-Based Tests — 64.3% Share:
NGS-based testing leads the test-type segment because it can evaluate multiple genes simultaneously and provide broader genomic profiling. Its role in identifying ESR1 mutations supports treatment planning within precision oncology workflows.
Plasma — 6.3% CAGR:
Plasma testing is expected to record the strongest growth among sample types. Its connection with liquid biopsy enables mutation detection from blood samples without requiring an invasive tissue biopsy, supporting repeated genomic monitoring.
Hospital-Associated Labs — 52.65% Share:
Hospital-associated laboratories remain the largest end-user segment because they have access to specialized diagnostic equipment and work directly with oncology teams. Their ability to handle NGS and PCR-based assays supports continued adoption.
Country-Level Performance
- China – 7.2% CAGR (2025–2035): Rising breast cancer incidence, personalized medicine adoption, early-diagnosis initiatives and precision diagnostics.
- Japan – 3.3% CAGR (2025–2035): Increasing clinical use of precision oncology in breast cancer care.
- Spain – 2.7% CAGR (2025–2035): Growing focus on precision medicine and genetic profiling.
- United Kingdom – 2.1% CAGR (2025–2035): Increasing demand for advanced breast cancer diagnostic capabilities.
- United States – 1.7% CAGR (2025–2035): NGS advancement, liquid biopsy adoption, precision medicine and targeted therapies.
- Germany – 1.6% CAGR (2025–2035): Adoption of advanced molecular diagnostics and precision oncology.
The report identifies China as the fastest-growing country in the market. China’s market is estimated at USD 5.36 million in 2025, with growth supported by increasing breast cancer incidence, stronger awareness of personalized medicine, government efforts around cancer control and early diagnosis, and innovation in precision diagnostics.
The United States remains a major market for breast cancer diagnostics and research despite its comparatively lower forecast CAGR. FMI cites advanced NGS capabilities, increasing liquid biopsy adoption, precision medicine, targeted therapies, and established cancer research infrastructure as factors supporting demand. The United States market is estimated at USD 20.3 million in 2025.
👉 Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-16943
Market Drivers, Restraints and Opportunities
Rising Precision Medicine Adoption
ESR1 mutations have clinical relevance in metastatic breast cancer because they can influence response to endocrine therapies. Accurate mutation identification therefore supports molecular characterization and treatment planning. Increasing use of precision medicine is expected to sustain demand for specialized diagnostic testing.
Liquid Biopsy Creates Growth Opportunities
The increasing need for minimally invasive cancer diagnostics is creating opportunities for plasma-based testing. Liquid biopsy can use circulating tumor DNA to identify mutations through blood samples and can support more frequent monitoring when tumor characteristics change during treatment.
Interpretation Complexity Remains a Constraint
Interpretation of ESR1 genetic variants remains challenging because the clinical significance of individual mutations can vary. Differences in scientific findings and the absence of universally standardized interpretation guidelines can complicate the translation of genomic results into treatment decisions.
The heterogeneity of ESR1 mutations also complicates targeted-treatment development, while limited availability of specific therapies can restrict the ability to tailor treatment around individual genetic profiles.
Competitive Landscape
The competitive environment is centered on molecular diagnostics, liquid biopsy technologies, NGS platforms and PCR-based testing. FMI identifies APIS Assay Technologies, Illumina, GENCURIX, RainSure Scientific, NeoGenomics Laboratories, Sysmex Corporation, ASURAGEN and Guardant Health among the key players.
Bio-Techne, through its Asuragen division, offers the QuantideX qPCR ESR1 exoMutation Kit with the ExoLution Plus cfDNA and exoRNA Isolation Kit. Guardant Health provides Guardant360 CDx for liquid-biopsy-based genomic testing, while Foundation Medicine offers FoundationOne CDx and FoundationOne Liquid genomic profiling platforms.
Recent Industry Developments
- June 2023: NeoGenomics announced that its RaDaR personalized liquid biopsy assay obtained pan-cancer commercial coverage from Blue Shield of California.
- December 2022: Guardant Health collaborated with AstraZeneca to pursue development, regulatory approval and commercialization of Guardant360 CDx as a companion diagnostic for identifying patients with ESR1-mutated metastatic breast cancer.
Analyst Perspective
“The ESR1 mutated metastatic breast cancer diagnostics market is expected to move toward faster mutation detection and therapy selection. Diagnostic companies with validated liquid biopsy tools and scalable NGS platforms are likely to gain preference among oncology labs.”
— Anurag Sharma, Principal Consultant for Healthcare at Future Market Insights.
Access the full report: https://www.futuremarketinsights.com/reports/esr1-mutated-metastatic-breast-cancer-diagnostics-market
Frequently Asked Questions
- What is the projected size of the ESR1 mutated metastatic breast cancer diagnostics market by 2035?
The market is projected to reach USD 92.92 million by 2035, up from USD 64.61 million in 2025, at a 3.7% CAGR. - Which test type dominates the market?
NGS-based tests are expected to account for 3% of the market share in 2025. - Which sample type is growing fastest?
Plasma testing is projected to grow at a 3% CAGR between 2025 and 2035. - Which end user holds the largest market share?
Hospital-associated laboratories are expected to hold 65% of market share in 2025. - Which country is expected to grow fastest?
China is projected to register the highest CAGR at 2% from 2025 to 2035. - What is the key opportunity in the market?
The growing adoption of liquid biopsy and minimally invasive molecular diagnostics provides a major opportunity for ESR1 mutation testing and repeated genomic monitoring.
Report Scope
- Market Size (2025): USD 64.61 million
- Market Forecast (2035): USD 92.92 million
- CAGR: 3.7%
- Historical Period: 2020–2024
- Forecast Period: 2025–2035
- Test Type: NGS-Based, PCR-Based
- Sample Type: Tissue, Plasma
- End Users: Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes
- Regions: North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, Middle East & Africa
- Countries Covered: United States, Germany, United Kingdom, Japan, China, Spain
- Key Players: APIS Assay Technologies, Illumina, GENCURIX, RainSure Scientific, NeoGenomics Laboratories, Sysmex Corporation, ASURAGEN, Guardant Health
About Future Market Insights
Future Market Insights, Inc. (FMI) is an ESOMAR-certified market research and consulting firm headquartered in Delaware, USA, with offices in the United Kingdom, the United Arab Emirates and India. FMI delivers syndicated and custom research across food and beverage, healthcare, chemicals, technology, packaging, consumer goods and industrial sectors.
Media Contact
Future Market Insights, Inc.
Phone: +1-347-918-3531
